Actionable news
All posts from Actionable news
Actionable news in EVOK: Evoke Pharma, Inc.,

Wednesday, July 27, 2016: Pharmaceutical/ Biotechnology Sector, Today's News Digest For Investors; Spotlight On Evoke Pharma (NASDAQ: EVOK) 3 comments

- Anavex Biosciences (NASDAQ: OTCQX:AVXL) stock fell more than 40% today after investors were disappointed with the 31-week data from the on-going phase 2a study of ANAVEX 2-73 in Alzheimer's Disease. Press Release. Link to More Analysis from

- Sequenom (NASDAQ: SQNM) agreed to be acquired for $302 million by LabCorp (NYSE: LH). Press Release.

- FDA updates warnings for fluoroquinolone antibiotics. Press Release. We have earlier written a research report on Cempra (NASDAQ: CEMP), whose broad-spectrum, next-generation macrolide antibiotic Solithromycin stands to benefit from these news. Link to research report.

- Tokai (NASDAQ: TKAI): Link to excellent analysis by EP Vantage. The company stock fell hard after a failed phase-3 trial in prostate cancer earlier this week.

- FDA has accepted a BLA for Biomarin's (NASDAQ: BMRN) investigational therapy to treat a form of Batten's disease, a rare disorder. The PDUFA date for the application is 1/27/2017. The drug has Orphan Drug and Breakthrough Therapy designation for this indication. Press Release.

- Biomarin also presented positive proof-of-concept data for its investigational gene therapy to treat hemophilia A at a scientific meeting. Press Release.

- UniQure (NASDAQ: QURE) announced positive phase 1/2 data from its investigational gene therapy in severe hemophilia B. Press Release.

- Today's review: What is new in the treatment of Alzheimer's Disease? Link to article.

- From STAT News: Nasal bacteria produce an antibiotic that kills MRSA. Link to article.

- ** Abbott (NYSE: ABT): CEO bought about $30 million worth of common stock today.

- ** Spotlight on Medivation (NASDAQ: MDVN). The company has been on our take-over candidate list. Chatter is that the acquisition is close and could happen within next week.

Other new additions to the existing list:

- Cannabinoid product companies:

- Versartis (NASDAQ: VSAR): detailed research report to be published tomorrow on SA.

- Ultragenyx (NASDAQ: RARE)

- Puma Biotechnology (NASDAQ: PBYI)

- Ironwood Pharma (NASDAQ: IRWD)

- Depomed (NASDAQ: DEPO)

- Pacira Pharmaceuticals (NASDAQ: PCRX)

- Opthotech Corp. (NASDAQ: OPTH)

- ** Spotlight on Eleven Biotherapeutics (NASDAQ: EBIO) which was again up 13.8% today. The stock has been in our top largest % gainers list for third consecutive day today. The company's focus is ocular therapeutics and announced acceptance of IND for EB-031 (a monoclonal antibody to treat...